Eli Lilly’s $15M investment deepens link to startup developing new class of RNA meds
Two months after Eli Lilly began an alliance with MiNA Therapeutics, a startup developing a new type of RNA therapy, the pharmaceutical giant is making […]
Two months after Eli Lilly began an alliance with MiNA Therapeutics, a startup developing a new type of RNA therapy, the pharmaceutical giant is making […]
AzurRx BioPharma Reports Positive Interim P-II Data of MS1819 + PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency Published: May 14, 2021 | […]
UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with […]
Shota: MiNA to receive $25M as up front and is eligible to receive $245M as milestones for each of five potential targets along with royalties […]
Takeda’s Alunbrig (brigatinib) Receives MHLW’s Approval as a 1L and 2L Treatment for ALK+ Advanced or Recurrent NSCLC Published: Jan 22, 2020 | Tags: Takeda, […]
Shots: MiNA to receive $267.6M in up front, exclusivity fee on first neurological target and will be eligible to receive research, development, regulatory and commercial […]
Copyright © 2024 | WordPress Theme by MH Themes